Vytorin is used to treat high cholesterol in adults and children over 10 years old. It is developed with a combination of ezetimibe and simvastatin. It works by reducing the amount of cholesterol in the body using ezetimibe, and reducing levels of LDL and triglycerides while increasing levels of HDL.


Common side effects of Vytorin include headaches, muscle pain, nausea, dizziness, fatigue and weakness. In rare cases it may lead to the development of severe muscle problems that can cause the muscle to break down, leading to acute kidney failure or death.


Clinicial studies have shown that Vytorin does not reduce plaque buildup in neck arteries, and is proven no more effective than the drug Zocor. Merck recently agreed to pay $688 million in lawsuits filed by shareholders. Investors alleged that Merck held back key information in a trial which tested Vytorin against its constituent part Zocor. The manufacturer is taking a $493 million charge on the settlement and admits no wrongdoing.